NFKB1 and cancer: Consistent with its effects on cancer, our previous study showed that ICS II protected against cerebral ischemic/reperfusion injury via inhibiting IκBα degradation and the subsequent phosphorylation of NF-κB, by which elevated levels of inflammatory cytokines are repressed (Deng et al., 2016).